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Abstract Carnitine-acylcarnitine translocase (CACT) defi-
ciency is a rare long-chain fatty acid oxidation disorder
(LC-FAOD) with high mortality due to cardiomyopathy or
lethal arrhythmia. Triheptanoin (UX007), an investigational
drug composed of synthetic medium odd-chain triglycer-
ides, is a novel therapy in development for LC-FAOD
patients. However, cases of its safe and efficacious use to
reverse severe heart failure in CACT deficiency are limited.
Here, we present a detailed report of an infant with CACT
deficiency admitted in metabolic crisis that progressed into
severe cardiogenic shock who was successfully treated by
triheptanoin. The child was managed, thereafter, on tri-
heptanoin until her death at 3 years of age from a cardio-
pulmonary arrest in the setting of acute respiratory illness
superimposed on chronic hypercarbic respiratory failure.
Introduction
Long-chain fatty acid oxidation disorders (LC-FAOD) are a
group of autosomal recessive inborn errors of metabolism
wherein genetic defects in specific mitochondrial enzymes
lead to an inability to convert long-chain fatty acids to
energy during periods of physiologic stress (Vockley et al.
2017). Amongst the most uncommon fatty acid oxidation
disorders, carnitine-acylcarnitine translocase (CACT) defi-
ciency is caused by mutations in SLC25A20 (Rubio-
Gozalbo et al. 2004). CACT is an essential component of
the carnitine cycle and is responsible for the importation of
long-chain fatty acids from the cytosol into mitochondria
for energy production via beta oxidation (Pande and
Murthy 1994; Vitoria et al. 2015). Clinical abnormalities
occur secondary to energy deprivation and accumulation of
potentially toxic long-chain fatty acid intermediates (Rubio-
Gozalbo et al. 2004). CACT dysfunction causes hypo-
ketotic hypoglycemia, hyperammonemia, and impairment of
fatty acid-dependent tissues, including the heart, liver, and
skeletal muscle. Presentation is typically early in life with a
relatively severe course, although minor phenotypes have
been reported (Pande and Murthy 1994).
Since the first report of CACT deficiency by Stanley and
colleagues in 1992, approximately 55 cases have been
reported in the medical literature (Stanley et al. 1992;
Vitoria et al. 2015). Treatment has focused on dietary
modification with frequent, carbohydrate-rich meals, avoid-
ance of fasting, restriction of fat intake, and supplementa-
t ion wi th medium chain t r ig lycer ides (MCT)
(Spiekerkoetter et al. 2009). However, the mortality rate
for CACT deficiency remains high (65%), with most deaths
occurring in the first year of life due to cardiac compli-
cations (Bonnet et al. 1999; Vitoria et al. 2015). The most
common cardiac manifestation is cardiomyopathy, but
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fatalities are more often reported due to conduction defects
and arrhythmias (Bonnet et al. 1999). For patients with
CACT deficiency and concomitant cardiac disease, current
treatment options are limited to supportive care.
Triheptanoin (UX007) is an investigational drug com-
posed of synthetic medium chain fatty acid which has been
used on a compassionate or emergency basis in patients
with LC-FAOD and severe cardiomyopathy (Roe and
Brunengraber 2015; Vockley et al. 2015, 2016). Here, we
present a detailed case of a patient with CACT deficiency
and cardiomyopathy devolving into severe cardiogenic
shock during a metabolic crisis. With failure of conven-
tional treatments, including MCT and carnitine supplemen-
tation, we hypothesized that triheptanoin may arrest further
cardiac deterioration and potentially lead to some recovery.
Case Report
The patient is a full-term female born to a 24-year-old G1P0
mother with no prenatal or antenatal complications via
normal spontaneous vaginal delivery who initially pre-
sented with hypoketotic hypoglycemia (glucose 12 mg/dL,
ref > 40 mg/dL) and hypothermia (95F, ref: 97.5–99.3F)
at 23 h of life. Her ammonia and lactate peaked at
319 mmol/L (ref: 64–107 mmol/L) and 4.1 mmol/L
(ref < 2 mmol/L), respectively, at 52 h of life. The
acylcarnitine profile demonstrated abnormal elevation of
numerous long-chain acylcarnitine species, particularly
palmitoyl- (16) and oleyl- (C18:1) acylcarnitine, suggestive
of carnitine palmitoyltransferase II or CACT deficiency.
SLC25A20 molecular analysis identified compound hetero-
zygosity for a previously reported c.84delT mutation and a
506-kb deletion on chromosome 3p21.31 which includes
the SLC25A20 gene (Eto et al. 2013, Haldeman-Englert
et al. 2009, Hsu et al. 2001). On day of life (DOL) 5, she
was started on MCT oil to supplement total parenteral
nutrition (TPN) and maternal breast milk (MBM). She was
discharged on a high MCT formula, maternal breast milk, a
carbohydrate module, and additional MCT oil, providing
145 kcal/kg, 1.5 g/kg protein, 33.5% fat calories, 9.5%
from long chain fats (LCFA), and 24% from MCT. Of note,
her initial echocardiogram (ECHO) at 4 days of age already
showed signs of biventricular hypertrophy but with normal
systolic function, i.e. left ventricular ejection fraction (EF)
64% and shortening fraction (SF) 41% (refEF: 49–86%,
refSF: 25–45%). Thus, she was actively followed by the
cardiac failure team.
At 5months, she presentedwith severemetabolic crisis with
hyperammonemia (314mmol/L) and acute kidney injury (AKI)
(creatinine 1.0 mg/dL, ref: 0.2–0.4 mg/dL). By hospital day 3,
despite nutritional support with high dextrose-containing TPN,
her left ventricular EF and SF had decreased from normal to
33% and 20%, respectively. Her cardiac enzymes rose
dramatically with a creatine kinase-MB isoenzyme (CK-MB)
of 119 ng/mL (ref < 1.7 ng/mL), troponin of 24 ng/mL
(ref< 0.1 ng/mL), and pro-basic natriuretic peptide (pro-BNP)
>30,000 pg/mL (ref < 300 pg/mL). Associated arrhythmias
(ectopy, diffuse STchanges, left bundle branch block, and QTc
prolongation >550 ms) ensued resulting in cardiogenic
shock, necessitating veno-arterial extra-corporal membrane
oxygenation (VA-ECMO) for 8 days. Upon recovery from
this episode, her cardiac function returned to baseline, i.e. EF
73% and SF 45%. She was discharged on a high MCT
formula, infant formula, a carbohydrate module, and addi-
tional MCT oil, providing 121 kcal/kg, 1.4 g/kg protein, 37%
fat calories, 8.4% from LCFA, and 28.6% from MCT.
At 10 months of age, she suffered another severe
metabolic crisis secondary to urinary tract infection and
gastroenteritis requiring admission to the pediatric intensive
care unit (PICU) for metabolic management and aggressive
fluid resuscitation due to moderate dehydration secondary
to emesis and diarrhea (stool output up to 30 mL/kg/day in
the first 3 days of hospitalization). To provide sufficient
calories, total parenteral nutrition (TPN) was started (15%
dextrose, 1.2 g/kg amino acids) with continuation of enteral
MCT oil, providing 107 kcal/kg/day, MCT providing 21%
of total calories. She slowly improved clinically and enteral
feedings were initiated on day 5 of hospitalization with
gradual advancement to bolus feeds and discontinuation of
TPN. She was thereafter transferred to the acute care ward.
However, on hospital day 8, she was transferred back to
the PICU for dehydration from continued diarrhea (stool
output >10 mL/kg/day) and oliguric renal failure (creati-
nine 0.9 mg/dL). Despite appropriate fluid and caloric
management (restarted TPN with 10% dextrose, 0.7 g/kg
protein, enteral MCT oil, providing 82 kcal/kg/day, with
MCT providing 32% of total calories), she developed
severe cardiogenic shock within 48 h with extreme tachy-
cardia (>200/min) and hypotension. She had deep ST-
depression with elevated cardiac enzymes, i.e. CK-MB and
troponin at 97.7 ng/mL and 17.2 ng/mL, respectively. Her
pro-BNP was >30,000 pg/mL, lactate peaked at 6.2 mmol/
L, and creatinine peaked at 1.2 (Table 1). With myocardial
ischemia, a strategy of using multiple low-dose dose vaso-
active agents was adopted, including calcium chloride up to
7 mg/kg/h, dopamine up to 7 mg/kg/min, epinephrine up to
0.05 mg/kg/min, and dobutamine up to 7 mg/kg/min,
targeting a mean arterial pressure of 50 mmHg, in con-
junction with a beta-blocker (esmolol up to 150 mg/kg/min)
targeting a heart rate <150/min to optimize cardiac output.
She was also started on stress-dose steroids at 50 mg/m2/
day.
Her overall dismal prognosis made her a poor ECMO
candidate. On hospital day 13 (EF 24.9%, SF 12.4%, CK-
MB 107 ng/mL, troponin 39.9 ng/mL) after obtaining
authorization from the Food & Drug Administration (FDA),
the Institutional Review Board (IRB), and parental consent,
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MCT oil was stopped and triheptanoin was initiated via
naso-jejunal tube at a dosage of 30 kcal/kg/day (34% of
total calories). Three days after initiation of triheptanoin, a
repeat ECHO showed normalization of left ventricular EF
and SF (Fig. 1) and a >4-fold reduction in cardiac enzymes
(Table 1). In the same time frame, all vasoactives were
successfully weaned off.
Her enteral diet was advanced to include a very low fat
elemental product, infant formula, and a protein module,
which, with triheptanoin, provided 90 kcal/kg/day and
1.4 g/kg/day protein with 43% calories from fat, 11% from
LCFA, and 32% from triheptanoin. Walnut oil was added as
a source of essential fats. She was eventually extubated 18
days after triheptanoin initiation and discharged home a
week later. ECHO prior to discharge showed biventricular
hypertrophy with good biventricular systolic and diastolic
function.
She continued triheptanoin after discharge; dosing was
changed to four times a day for ease of administration.
Since initiation of triheptanoin, she had two subsequent












Day of hospitalization – 1 8 10 13 16
Ammonia <30 mmol/L 143 241 52 40 32
Lactate <2 mmol/L 0.6 2.8 3.2 1.8 1.9
Creatinine 0.1–0.6 mg/dL 0.4 0.9 1.2 0.9 0.5
Creatinine kinase, total <250 U/L N.C.a N.C. 1,990 713 443
Creatinine kinase, MB <1.7 ng/mL N.C. N.C. 97.7 107 24.7
Troponin <0.1 ng/mL N.C. N.C. 17.2 40 7.9
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Fig. 1 Cardiac function plotted over time. Prior to and even at
admission to ICU, the patient maintained normal biventricular systolic
and diastolic function, despite left ventricular hypertrophy. When she
suffered cardiogenic shock, ejection fraction (EF) and shortening
fraction (SF) both declined precipitously to approximately 25% and
12%, respectively. After 72 h of triheptanoin therapy, her EF and SF
returned to baseline. She continued triheptanoin therapy till her death.
Prior to death, her cardiac function was close to her baseline
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admissions, one for hyperammonemia due to acute gastro-
enteritis and a second for dehydration in the setting of
C. difficile colitis. During both illnesses, her cardiac
function remained stable. At her 20-month clinic visit, she
was in overall good health and had developed the ability to
sit independently. At 32 months of age, she was diagnosed
with obstructive sleep apnea, hypoventilation, hypotonia
and hypercarbic respiratory failure requiring noninvasive
positive pressure ventilation.
At 3 years of age, she suffered a cardiac arrest
precipitated by mucus plugging in the setting of a viral
upper respiratory tract infection; care was withdrawn after
admission due to devastating neurologic injury. ECHO
performed after admission demonstrated no deterioration in
function (Fig. 1, day of life 1,139: EF 70%, SF 32.6%).
Additionally, her EKGs and rhythm strips showed normal
sinus rhythm (NSR).
Discussion
Fatty acid oxidation generates energy during fasting and
stress by directly supplying reducing equivalents for
mitochondrial oxidative phosphorylation and providing
acetyl-CoA to the tricarboxylic acid (TCA) cycle. Loss of
this energy source along with impaired ketone body
production during metabolic crisis leads to increased
demand on the TCA cycle. Medium chain triglycerides
are metabolized to the 2-carbon substrate acetyl-CoA that
can enter the TCA cycle. In addition to two molecules of
acetyl-CoA, triheptanoin provides a 3-carbon propionyl-
CoA which can directly enter the TCA cycle as succinyl-
CoA through the actions of propionyl-CoA carboxylase and
methylmalonyl-CoA mutase (Roe and Mochel 2006).
In this manner, triheptanoin provides appropriate substrate
balance for the TCA cycle.
Triheptanoin, as treatment for fatty acid oxidation
disorders, was first reported in the treatment of three
patients with the cardiomyopathic form of very-long-chain
acyl-CoA dehydrogenase deficiency (Roe et al. 2002). In
these patients, congestive heart failure, rhabdomyolysis,
and muscle weakness improved, as did the severity and
frequency of metabolic decompensation. Results of a larger
series of 20 patients with various long-chain fatty acid
oxidation disorders treated with triheptanoin as part of a
compassionate use protocol showed significant decreases
in mean hospital days per year and hypoglycemia event
rates. Of the 12 patients in the series that had cardiomyop-
athy at the start of triheptanoin therapy, 8 improved, 3
remained stable, and 1 required cardiac transplantation.
The single CACT deficiency patient in this cohort had
cardiomyopathy that improved, with ejection fraction
increasing to 67% from 35% pre-treatment (Vockley et al.
2015). A subsequent case series of ten patients with LC-
FAOD and acute heart failure in whom triheptanoin had
been initiated for compassionate or emergency use dem-
onstrated return of normal EF within 3 weeks of initiation;
only two of these patients had CACT deficiency (Vockley
et al. 2016). Now, a single-arm, open-label, multicenter
Phase 2 trial has been published demonstrating safety and
efficacy in pediatric and adult patients at 24 weeks of
treatment; CACT deficiency patients were excluded from
this study due to the severity of the condition (Vockley
et al. 2017).
Patients with CACT deficiency are at high risk for
morbidity and mortality with each fasting period or ill-
ness. Despite maximizing supportive measures during a
severe metabolic crisis, our patient’s condition declined
precipitously. Only after providing triheptanoin did car-
diac function improve gradually but dramatically, with
ejection fraction rising from 24.9 to 73.7%. With continu-
ation of triheptanoin as a routine part of her nutritional
management, her cardiac function remained preserved
through the next 2 years of life. She even developed the
ability to sit independently. Her ultimate death seemed
linked to a primary respiratory event rather than a cardiac
one. Given the paucity of clinical experience with tri-
heptanoin use specifically in CACT deficiency, our report
highlights the safe and efficacious use of triheptanoin in
acute heart failure in this subset of patients. Triheptanoin
may provide a therapeutic alternative that could poten-
tially lead to improved outcomes for CACT deficiency
patients.
Synopsis
This report details the safe use of triheptanoin to reverse
cardiogenic shock in the case of a patient with carnitine-
acylcarnitine translocase deficiency suffering severe meta-
bolic crisis devolving into acute heart failure.
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